West Nile virus to spread to remote areas of Quebec due to climate change, study says
A recent study by the Public Health Institute suggests warmer temperatures could lead to a surge in West Nile virus cases and that it could spread to more remote regions of the province for the first time.
Get weekly health news
Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy
The virus is often found in Quebec's larger city centres, especially around Montreal. But by 2080, the virus could migrate, going as for as Gaspé and even north to the Abitibi region.
As Global's Franca Mignacca reports, warming weather coupled with increased precipitation is expected to increase its spread, as well as other mosquito and tick-born diseases.
For the full story, watch the video above.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
26 minutes ago
- Globe and Mail
Hemophilia Pipeline Outlook Report 2025: Key 80+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Hemophilia Pipeline Insight, 2025,' report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in Hemophilia pipeline landscape. It covers the Hemophilia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hemophilia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Hemophilia Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Hemophilia Pipeline Outlook Report Key Takeaways from the Hemophilia Pipeline Report In July 2025, Novo Nordisk A/S announced a study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. In July 2025, Pfizer announced a study to establish baseline prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study. In July 2025, Regeneron Pharmaceuticals announced a study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy. DelveInsight's Hemophilia pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hemophilia treatment. The leading Hemophilia Companies such as Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Promising Hemophilia Pipeline Therapies such as NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Discover how the Hemophilia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Hemophilia Clinical Trials and Studies Hemophilia Emerging Drugs Profile SerpinPC: Centessa Pharmaceuticals SerpinPC, a specific inhibitor of activated protein C (APC), for the treatment of hemophilia A and hemophilia B. SerpinPC has been observed to be well-tolerated in the clinical setting, associated with promising reductions in bleeding rates, and has PK suitable for infrequent subcutaneous dosing without the need for factor replacement. SerpinPC has human genetic target validation and established proof of concept Phase 2a clinical data. Fitusiran: Alnylam Pharmaceuticals Fitusiran (ALN-AT3) is a subcutaneously administered, investigational RNAi therapeutic targeting antithrombin (AT) in development for the treatment of hemophilia and rare bleeding disorders (RBDs) by their collaborators at Sanofi Genzyme. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Hemophilia. ASC 618: ASC Therapeutics ASC618 is an AAV8-based gene therapy for the treatment of hemophilia A, affecting approximately 1 of every 5000 live-born males. ASC618 incorporates a novel liver-specific promoter and a bioengineered, codon-optimized B domain-deleted FVIII variant; in preclinical studies, ASC618 exhibits at least a 10-fold increase in the biosynthesis and secretion of FVIII compared with native human FVIII bioengineered gene constructs. ASC618 has the potential to increase durability of clotting factor biosynthesis and secretion by minimizing cellular stress and induction of the unfolded protein response, which may lead to diminished FVIII production from liver cells. ASC Therapeutics will conduct a phase 1/2 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of ASC618. The program received IND clearance from the U.S. Food and Drug Administration. The Hemophilia Pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Hemophilia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hemophilia Treatment. Hemophilia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Hemophilia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hemophilia market. Get a detailed analysis of the latest innovations in the Hemophilia Pipeline. Explore DelveInsight's expert-driven report today! @ Hemophilia Unmet Needs Hemophilia Companies Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intra-articular Intraocular Intrathecal Intravenous Ophthalmic Oral Parenteral Subcutaneous Topical Transdermal Products have been categorized under various Molecule types such as Oligonucleotide Peptide Small molecule Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key Hemophilia Developments @ Hemophilia Market Drivers and Barriers, and Future Perspectives Scope of the Hemophilia Pipeline Report Coverage- Global Hemophilia Companies- Centessa Pharmaceuticals, Alnylam Pharmaceuticals, ASC Therapeutics, Spark Therapeutics, Freeline Therapeutics, BioMarin Pharmaceutical, Staidson Beijing BioPharmaceuticals, Pfizer, Sangamo Therapeutics, Amunix, Bioverativ, Novo Nordisk and others. Hemophilia Pipeline Therapies- NNC0365-3769 (Mim8) PPX, Mim8, STSP-0601 for Injection, Fitusiran, Marstacimab, Fitusiran, BPA prophylaxis, Concizumab, PF-06741086 and others. Hemophilia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Hemophilia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Hemophilia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Hemophilia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Hemophilia: Overview Pipeline Therapeutics Therapeutic Assessment Hemophilia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Fitusiran: Alnylam Pharmaceuticals Mid Stage Products (Phase II) SerpinPC: Centessa Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) Drug name: Company Name Preclinical and Discovery Stage Products Drug name: Company Name Inactive Products Hemophilia Key Companies Hemophilia Key Products Hemophilia- Unmet Needs Hemophilia- Market Drivers and Barriers Hemophilia- Future Perspectives and Conclusion Hemophilia Analyst Views Hemophilia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Global News
an hour ago
- Global News
Toxic drug deaths down in May and June, BC Coroners Service reports
The number of deaths due to toxic drugs fell to below 150 people per month for May and June in British Columbia, a downward trend from the same months last year. The BC Coroners Service says in a statement that the province recorded 145 deaths in May compared with 181 for the same month last year. There were 147 overdose deaths in June, down from 185 the year before. The BC Coroners Service and government have also started releasing the occupation of those who died, and the two most common jobs are trades, transport and equipment operation, as well as sales and service. 2:16 Future of B.C. safer supply program in doubt The statement says 69 per cent of the drug-toxicity deaths are adult men between the ages of 30 and 59, while 78 per cent of all deaths are male. Story continues below advertisement The statistics show that the opioid fentanyl is the most common substance detected in those who died this year, followed by methamphetamine and cocaine. Get daily National news Get the day's top news, political, economic, and current affairs headlines, delivered to your inbox once a day. Sign up for daily National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy 'Forty-seven per cent of deaths reported occurred in a private residence, compared with 21 per cent outdoors,' the statement says. Smoking continues to be the primary mode of consumption of unregulated toxic drugs, with 64 per cent of investigations indicating the person who died smoked their substances, the statement says The highest toxic drugs death rate this year is in the Northern Health region with 44 deaths per 100,000 people, and the cities with the highest tolls are Vancouver, Surrey and Greater Victoria.
Global News
4 hours ago
- Global News
After feds cut funding, B.C. keeps ‘safer supply' programs running — for now
Despite concerns that prescribed alternatives, such as hydromorphone, are being diverted to the street drug supply, the B.C. government has stepped in to keep five safer supply programs operating for another year after federal funding for the pilot projects ended on March 31. Between 2017 and March 2025, Health Canada says it funded $126 million through its Substance Use and Addictions Program (SUAP) on 31 pilot projects across the country that were designed to evaluate approaches for providing 'prescribed alternatives' in response to the toxic drug and overdose crisis. Federal funding for the projects 'sunset as planned' at the end of March, Health Canada said in a statement. 2:12 Report slams B.C. drug policy Five of the programs previously funded via SUAP are in B.C., according to the B.C. Ministry of Health, which has since provided funding to all of them for one year through March 2026. Story continues below advertisement Vancouver Coastal Health's Safer Alternative for Emergency Response (SAFER) Initiative and Kilala Lelum, and three projects in the Vancouver Island Health Authority (AVI SAFER in Victoria, Nanaimo, and the North Island) 'remain operational with contingency measures in place,' the B.C. Ministry of Health told Global News on Wednesday. Pharmacist Gary Siu, who has owned and operated Garlane Pharmacy on East Hastings Street in Vancouver for more than 40 years, said he suspects politics may be behind Health Canada's cessation of funding for the safer supply initiatives. 'It's controversial,' Siu told Global News in an interview on Wednesday. 'There's good points and bad points, the bad points, people complained about diversion of the hydromorphone to the illegal supply.' Get weekly health news Receive the latest medical news and health information delivered to you every Sunday. Sign up for weekly health newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy When asked if drug diversion played a role in the decision to end funding for these programs, Health Canada did not respond. 'The approach that had previously been taken around prescribed alternatives was not working,' B.C. Premier David Eby acknowledged on Tuesday. In February, the B.C. government announced it was overhauling its safe supply program to make sure prescribed medications are being used by the people they are intended for. 2:23 B.C. overhauls safe supply program The province's take-home safe supply program has changed to a witness model, with new patients required to consume their drugs under the watch of health professionals, while existing patients are transitioned to witnessed consumption. Story continues below advertisement The B.C. Ministry of Health said evidence shows the prescribed alternatives program has helped separate people from the unregulated drug supply, manage their substance use and withdrawal symptoms, while helping connect them to voluntary health and social supports, including substance use treatment. 'We're going to continue to work with public health, with people of lived experience, with the Indigenous communities and people across the province to ensure that we are keeping people alive, getting them into treatment and helping them rebuild their lives,' said Eby. 'There was significant diversion,' said Opposition B.C. solicitor general and public safety critic, Elenore Sturko. 'We know that has caused harm in our community, and whether or not the ethics of this program can still justify its existence, we don't know.' While shifting to a fully witnessed model is a good first step, Sturko said, recovery should be the focus, and the government has provided no evidence that safer supply works to help people recover. 'It doesn't surprise me they're continuing the funding, but I am pleased to se,e actually, that the feds have ended the funding and it's clear that this is something that they want to move away from,' Sturko told Global News. 1:42 B.C. Conservatives release leaked Ministry of Health presentation on safe supply Prescribed alternatives were dispensed to 2,960 people in B.C. in May, according to the Ministry of Health. Story continues below advertisement Pensioner Dave McAleer, 72, said he's been receiving prescribed methadone for 'too long' but it keeps him off street drugs most of the time. 'They're trying to get me down,' the Downtown Eastside resident told Global News on Wednesday. Siu said he's noticed a trend of doctors slowly reducing doses for safer supply patients, from what was initially a maximum of 14 hydromorphone tablets per day. 'Now they are phasing out like each month, each new prescription, instead of 14, they're getting 10, eight and slowly phasing it out,' Siu said. 'And then the people who legitimately require it are getting short-ended a little bit and pushed out.' The longtime pharmacist said it's a complex problem without a clear-cut solution. 'Because people are addicted, you want to help them, you don't want them to commit crimes or anything like that,' Siu said. 'Hopefully, they get back on the right path.' Vancouver Coastal Health told Global News it will continue to work with the B.C. Ministry of Health on strategies to support clients of SAFER and Kilala Lelum after March 2026. 'Our priority remains ensuring the most vulnerable people have access to critical health services and a range of options to address their unique needs and circumstances,' VCH said in a statement. Story continues below advertisement Through SUAP, Health Canada said it continues to fund projects from prevention and education to harm reduction and treatment.
